- Home
- IBIO
IBIO
iBio Inc.
as 01-17-2025 4:00pm EST
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 24.3M | IPO Year: | N/A |
| Target Price: | $4.87 | AVG Volume (30 days): | 132.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.02 - $4.98 | Next Earning Date: | 02-07-2025 |
| Revenue: | $175,000 | Revenue Growth: | 250.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of iBio Inc. (IBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Arkowitz David | IBIO | Director | Jan 10 '25 | Buy | $2.72 | 18,382 | $49,999.04 | 18,382 | |
| Brenner Martin | IBIO | See Remarks | Jan 10 '25 | Buy | $2.72 | 9,191 | $24,999.52 | 18,316 | |
| Sender Gary | IBIO | Director | Jan 10 '25 | Buy | $2.72 | 9,191 | $24,999.52 | 9,191 | |
| Banjak Marc | IBIO | Chief Legal Officer | Jan 10 '25 | Buy | $2.72 | 9,191 | $24,999.52 | 11,066 | |
| Clark William D | IBIO | Director | Jan 10 '25 | Buy | $2.72 | 1,838 | $4,999.36 | 1,838 | |
| Parada Antonio Bernardino Guimaraes | IBIO | Director | Jan 10 '25 | Buy | $2.72 | 183,823 | $499,998.56 | 183,823 |
Latest iBio Inc. News
IBIO Breaking Stock News: Dive into IBIO Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
iBio Announces New Investments from Board Members and Officers
GlobeNewswire
12 days ago
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
TipRanks
16 days ago
iBio Expands Pipeline with New Antibody Agreement
Benzinga
17 days ago
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform
GlobeNewswire
17 days ago
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
GlobeNewswire
2 months ago
iBio Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
2 months ago
iBio Reports Fiscal First Quarter 2025 Financial Results
GlobeNewswire
3 months ago
iBio and AstralBio Provide Update on Myostatin Program for Obesity
Compare IBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IBIO iBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.